GSK to sell two travel vaccines to Danish biotech firm

FILE PHOTO: The GlaxoSmithKline (GSK) logo is seen on top of GSK Asia House in Singapore, March 21, 2018. REUTERS/Loriene Perera/File Photo

(Reuters) – GlaxoSmithKline Plc said on Monday it will sell two travel vaccines to Denmark-based biotechnology company Bavarian Nordic for an upfront payment of 301 million euros ($335.71 million).

The sale of anti-rabies treatment Rabipur and Encepur, used for the prevention of tick-borne encephalitis, by the British drugmaker includes milestone payments of up to 495 million euros.

Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Arun Koyyur

Our Standards:The Thomson Reuters Trust Principles.

Related posts

‘Stem-cell tourism’ needs tighter controls, say medical experts


Primary care access tied to fewer sexually transmitted infections


Arena’s heart-lung drug succeeds in mid-stage study, shares soar


Leave a Comment